Table 2 Comparison of patient demographics between patients with high ATPD (≥ 44 HU) and those with low ATPD (< 44 HU).
From: Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer
High ATPD | Low ATPD | P value | |
|---|---|---|---|
No. pts | 110 | 120 | |
Age, years | 71 (63–77) | 75 (70–79) | < 0.01 |
Male, n (%) | 99 (90) | 85 (71) | < 0.01 |
BMI, kg/m2 | 21.5 (18.8–23.6) | 22.7 (20.7–25.2) | < 0.01 |
ECOG PS ≥ 1, n (%) | 12 (11) | 28 (23) | 0.01 |
CCI ≥ 1, n (%) | 46 (42) | 59 (50) | 0.23 |
Neutrophil-to-lymphocyte ratio | 2.1 (1.5–3.3) | 2.2 (1.6–3.0) | 0.86 |
Serum albumin, g/dL | 4.0 (3.6–4.3) | 3.9 (3.6–4.2) | 0.17 |
Psoas muscle index, cm2/m2 | 4.9 (3.8–5.7) | 4.2 (3.3–5.4) | 0.01 |
Neoadjuvant chemotherapy, n (%) | 27 (25) | 38 (32) | 0.22 |
Cystectomy approach, n (%) | 0.49 | ||
Open | 88 (80) | 101 (84) | |
Laparoscopic | 11 (10) | 12 (10) | |
Robotic | 11 (10) | 7 (6) | |
Urinary diversion, n (%) | < 0.01 | ||
Cutaneous ureterostomy | 39 (35) | 52 (43) | |
Ileal conduit | 54 (49) | 64 (53) | |
Neobladder | 17 (15) | 4 (3) | |
Pathological diagnosis, n (%) | 0.98 | ||
UC | 100 (91) | 109 (91) | |
Non-UC | 10 (9) | 11 (9) | |
Pathological T stage, n (%) | 0.16 | ||
pT0-T2 | 73 (66) | 69 (58) | |
pT3-T4 | 37 (34) | 51 (43) | |
Lymph node metastasis | 0.89 | ||
pN negative | 90 (82) | 99 (83) | |
pN positive | 20 (18) | 21 (18) | |
CIS concurrent | 0.14 | ||
Yes | 28 (25) | 21 (18) | |
No | 82 (75) | 99 (83) |
